Abstract
Omalizumab is a monoclonal antibody that decreases IgE levels and has been shown to decrease asthma exacerbations, emergency care visits, and hospitalizations when added on to standard medical therapy for moderate–severe persistent asthma. We describe the results of omalizumab treatment in children 6 to 18 years old with severe asthma at a single pediatric medical center. This is a retrospective analysis of 27 children, 13 ± 3 years old, with severe asthma evaluated before and after treatment with omalizumab. Their baseline data were compared to 34 children with moderate–severe persistent asthma, 11 ± 3 years old, and to 65 children with mild persistent asthma, 10 ± 3 years old. Medication use, pulmonary function tests, IgE levels, and aeroallergen sensitivity differences were analyzed among moderate to severe asthmatics and mild asthmatics. Pulmonary function tests, quality of life questionnaires, and reduction of inhaled corticosteroid (ICS) doses were evaluated during omalizumab treatment. Children wit...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.